Top Biotech Stocks to Buy and Hold Long-Term.
With growing interest in obesity treatments, Goldman Sachs just raised its market estimates from $100 billion to $130 billion.
“The estimate was revised as the firm projects the number of Americans on anti-obesity drugs could reach ~19M by 2030, up from its previous estimate of ~15M. This indicates a ~17% market penetration among U.S. adults,” as noted by Seeking Alpha.
While that’s certainly great news for obesity treatment heavyweights like Eli Lilly (LLY) and Novo Nordisk (NVO), it’s also fueling momentum in up-and-coming treatment stocks, like:
Viking Therapeutics (SYM: VKTX)
With Viking Therapeutics, the company is seeing good success with its GLP-1 obesity drug trials. It already reported that its Phase 2 VENTURE trial successfully achieved is primary endpoint and all secondary endpoints. It also said patients receiving VK-2735 demonstrated weight loss after 13 weeks, rating up to 14.7% from baseline weight.
Better, VKTX is about to start Phase 2 trials of its once-a-day weight loss pill. Viking said patients who received the pill once a day lost up to 5.3% of their weight on average, or up to 3.3% more than those who took a placebo, at 28 days, as noted by CNBC.
Altimmune (SYM: ALT)
Altimmune could get swept up in a potential $130 billion weight loss drug treatment boom. All thanks to blockbuster demand for such treatments.
Even better, it may also have a leg up on its competition.
“Data from a 48-week trial showed that about 74.5% of weight loss was linked to fat tissue. About 25.5% was linked to lean mass, which may give it a leg up against the competition,” according to ALT’s press release.
The company believes the preservation of lean mass with weight loss is critical. In fact, severe medical outcomes, such as musculoskeletal issues and bone fractures, can occur if a person loses too much lean mass during weight loss.
Structure Therapeutics (SYM: GPCR)
GPCR is moving forward with its 36-week Phase 2b obesity study later this year. Two, GPCR believes its GSBR-1290 obesity treatment is “uniquely positioned as an oral, non-peptide small molecule GLP-1 receptor agonist that can be manufactured at scale and significantly help address the growing obesity epidemic, which current peptide GLP-1s are not able to do.”
If you’re looking for opportunities in the market here’s another one you should consider!
I’ve scoured the market and found that an FDA APPROVAL COULD SEND THIS STOCK UP 46,751%
Whenever the FDA approves a new drug…
Timely investors could see 300-400% returns overnight…
CCXI returned 281% to investors in one day…
Relmada shot up 971% in 9 months…
Agile soared 305% in 5 months…
